Funding newsPublished September 21, 2026

BIOPIGMENTA Raises $30.0K Pre-Seed Funding

Recently funded · $30.0K Pre-seedManufacturingView source

Get the full BIOPIGMENTA company profile

Access contacts, investors, buying signals & more

BIOPIGMENTA has raised $30K in pre-seed funding from the Raising Starts program and the Science and Technology Park Belgrade.

The company makes bio-inks powered by non-GMO bacterial pigments, positioning them as a biodegradable replacement for synthetic dyes.

From the source

BIOPIGMENTA · Sep 21, 2026

🚀 Big News! During the months of July and August the BIOPIGMENTA team enrolled in the "Raising Starts" pre-seed accelerator program under the Science and Technology Park Belgrade. Out of 211 initial teams, 26 advanced to Phase 1, and only 11 teams were selected for Phase 2, along with 30.

000 CHF in funding. We are absolutely thrilled to announce that our team has officially secured funding from the "Raising Starts program" and will be entering Phase 2 as a registered company. Participating in this competition has been a great and exciting journey. From sharing our vision and meeting inspiring people to refining our pitch, we had a fantastic time throughout the entire process. A

Unlock the full source

CEO quotes, investor details and growth metrics

Start free trial

Other recently funded companies

View all

Piomic Medical
Piomic Medical is a Swiss ETH Zurich startup and emerging regenerative medtech company pioneering deep tissue regeneration through physical stimulation therapies, with headquarters in Zurich and U.S. operations in Chicago. Our proprietary COMS® platform (Concurrent Optical and Magnetic Stimulation) delivers synergistic stimulation designed to modulate key regenerative pathways, including ion channel signaling, nitric oxide production, and mitochondrial activity, to support cellular metabolism and facilitate tissue repair. Our flagship device, the COMS® One Therapy System, is a portable device for treatment of non-healing wounds, designed for seamless use across hospital, outpatient, and home-care settings. It has received FDA Breakthrough Device Designation and is CE-marked under the EU Medical Device Regulation (MDR). Piomic’s strong and growing clinical portfolio includes two active studies: • MAVERICKS – a randomized, double-blinded FDA IDE pivotal trial in therapy-refractory diabetic foot ulcers in the U.S. • NAZARÉ – a multicenter real-world evidence study evaluating COMS® therapy in chronic vascular leg ulcers across European wound centers. Beyond wound healing, the COMS® platform has potential applications in various other disease areas, such as sports medicine, aesthetics, ophthalmology and infection management. Piomic’s mission is to advance regenerative therapies and improve outcomes for patients with difficult-to-treat conditions worldwide. 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘯𝘰𝘵𝘦: 𝘛𝘩𝘦 𝘊𝘖𝘔𝘚® 𝘖𝘯𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘚𝘺𝘴𝘵𝘦𝘮 𝘪𝘴 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘳𝘦𝘤𝘦𝘪𝘷𝘦𝘥 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘰𝘳 𝘊𝘢𝘯𝘢𝘥𝘢.
$25.0M Series b

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#	Company	Round	Amount	Date
1	Shockwave Medical United States	Unknown	$13.1B	2y ago
2	NeuroEM Therapeutics United States	Unknown

Other recent Pre-seed rounds

Companies that recently closed a Pre-seed round.

#	Company	Round	Amount	Date
1	Spinoto	Pre-seed	$149.0K	today
2	UCANACT The Netherlands	Pre-seed	$917.1K	today
3